ArticleBlood advances2019
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches.Frontiers in oncology · 2021Pooled it
- Two Decades ofCancers · 2026Review
- Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.American journal of hematology · 2026Review
- Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification.Current hematologic malignancy reports · 2026Review
- [Myelodysplastic neoplasms with acute myeloid leukemia-like mutations: clinical features, molecular profiles, and prognosis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.Blood cancer discovery · 2025Article
- Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic Profiles.European journal of haematology · 2025Article
- What Is Acute Myeloid Leukemia?EJHaem · 2025Review
- Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?The oncologist · 2025Review
- AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.Blood advances · 2025Article
- Article
- Distinct mutation features and its clinical significance in myelodysplastic syndromes with normal karyotype.Annals of hematology · 2024Article
- Recent advances in AML with mutated NPM1.International journal of hematology · 2024Review
- Integrating holotomography and deep learning for rapid detection of NPM1 mutations in AML.Scientific reports · 2024Article
- What is new in acute myeloid leukemia classification?Blood research · 2024Review
- Infrequent Presentations of ChronicCancers · 2024Review
- Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.Blood cancer discovery · 2024Review
- The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.Genes, chromosomes & cancer · 2023Article
- Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.American journal of hematology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 1 country.
Funding
Abstract
Nucleophosmin (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.